Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration

Ferric carboxymaltose (FCM) is a novel iron formulation increasingly prescribed due to its effectiveness and fast infusion time. FCM administration can cause an asymptomatic hypophosphataemia secondary to fibroblast growth factor 23 (FGF23) dysregulation. In patients with chronic iron needs, however...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMJ Case Rep
Hlavní autoři: Klein, Klara, Asaad, Shonda, Econs, Michael, Rubin, Janet E
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2018
Témata:
Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5775795/
https://ncbi.nlm.nih.gov/pubmed/29298794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2017-222851
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky